MEDICUS PHARMA LTD
MDCXNASDAQTrading Snapshot
- Day Range
- $0.33 – $0.33
- 52-Week Range
- $0.25 – $3.05
- Volume
- $2.65B
- Avg Volume
- $2.34B
- Shares Outstanding
- 22.0M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $620,202
- P/E Ratio
- -0.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.25
- Dividend Yield
- 0.00%
Why Investors Own MDCX
- ✓High-growth profile — revenue up +29.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MEDICUS PHARMA LTD
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock rose 11.63%
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi
Medicus Pharma obtained UAE approval for its PRECISION-E2 Phase 2a clinical trial testing Teverelix in endometriosis patients.
Medicus Pharma Receives FDA's Study May Proceed Letter Authorization For Its Investigational New Drug For SKNJCT-005 To Start Phase 2b Clinical Study To Treat Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
Top movers in Friday's after hours session
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Medicus Pharma Announces Positive FDA Feedback For Its Optimized Phase 2 Clinical Trial Of Teverelix In Men Following A First Episode Of Acute Urinary Retention
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
Curious about the stocks that are showing activity after the closing bell on Monday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.